X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (35) 35
index medicus (30) 30
humans (28) 28
medicin och hälsovetenskap (25) 25
medical and health sciences (24) 24
klinisk medicin (22) 22
clinical medicine (21) 21
middle aged (21) 21
adult (20) 20
cancer och onkologi (20) 20
female (20) 20
male (20) 20
cancer and oncology (19) 19
aged (18) 18
aged, 80 and over (14) 14
colorectal cancer (9) 9
prognosis (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
disease-free survival (8) 8
research (8) 8
bevacizumab (7) 7
cancer (7) 7
colorectal neoplasms - drug therapy (7) 7
rectal cancer (7) 7
care and treatment (6) 6
chemotherapy (6) 6
fluorouracil (6) 6
metastatic colorectal cancer (6) 6
streptococcus pneumoniae (6) 6
survival (6) 6
animals (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
fluorouracil - administration & dosage (5) 5
hematology, oncology and palliative medicine (5) 5
kras (5) 5
leucovorin (5) 5
mice (5) 5
microbiology (5) 5
panitumumab (5) 5
research article (5) 5
survival analysis (5) 5
treatment outcome (5) 5
virulence (5) 5
abridged index medicus (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
bacteria (4) 4
bacterial proteins - genetics (4) 4
camptothecin - administration & dosage (4) 4
camptothecin - analogs & derivatives (4) 4
capecitabine (4) 4
colon-cancer (4) 4
colorectal neoplasms - genetics (4) 4
colorectal-cancer (4) 4
genetic aspects (4) 4
leucovorin - administration & dosage (4) 4
metastasis (4) 4
mice, inbred c57bl (4) 4
radiotherapy (4) 4
rectal neoplasms - genetics (4) 4
risk factors (4) 4
streptococcus pneumoniae - genetics (4) 4
streptococcus pneumoniae - pathogenicity (4) 4
tumors (4) 4
adaptor proteins, signal transducing (3) 3
adenocarcinoma (3) 3
analysis (3) 3
antibiotics (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antibodies, monoclonal, humanized - therapeutic use (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
beta-catenin (3) 3
biological sciences (3) 3
biomarkers, tumor - metabolism (3) 3
cancer patients (3) 3
cancer research (3) 3
carrier proteins (3) 3
cetuximab (3) 3
cohort studies (3) 3
colorectal neoplasms - mortality (3) 3
colorectal neoplasms - pathology (3) 3
complications and side effects (3) 3
digestive system diseases (3) 3
dna-binding proteins (3) 3
drug therapy (3) 3
efficacy (3) 3
enzyme-linked immunosorbent assay (3) 3
epidemiology (3) 3
erlotinib (3) 3
fluorouracil - adverse effects (3) 3
follow-up studies (3) 3
gene (3) 3
gene expression (3) 3
gene expression profiling (3) 3
genetic loci (3) 3
genetics (3) 3
identification (3) 3
infectious diseases (3) 3
maintenance treatment (3) 3
medicine & public health (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ANNALS OF ONCOLOGY, ISSN 0923-7534, 09/2013, Volume 24, Issue 9, pp. 2342 - 2349
Journal Article
by Kubicka Prof, Stefan and Greil, R and André, T and Bennouna, J and Sastre, J and Van Cutsem, E and Von Moos, R and Österlund, P and Reyes-Rivera, I and Müller, T and Makrutzki, M and Arnold, D and Andel, J and Balcke, P and Benedicic, B and Eisterer, W and Fridrik, M and Jagdt, B and Keil, F and Kretschmer, A and Krippl, P and Oexle, H and Pecherstorfer, M and Samonigg, H and Schmid, M and Thaler, J and Tinchon, C and Weiss, H and Arts, J and De Man, M and Demolin, G and Janssens, J and Polus, M and Benczikova, B and Melichar, B and Prausova, J and Vitek, P and Andersen, F.Z and Jensen, B.B and Keldsen, N and Østerlind, K and Vistisen, K and Elme, A and Magi, A and Ojamaa, K and Ristamäki, R and Salminen, T and Ben Abdelghani, M and Bouche, O and Borg, C and Bouhier-Leporrier, K and Breysacher, G and Chone, L and Clavero Fabri, M.-C and Deplanque, G and Desseigne, F and Dourthe, L.-M and Ezenfis, J and Faroux, R and François, E and Garnier, C and Gaspard, M.-H and Hebbar, M and Illory, J.F and Kaminsky, M.-C and Lecomte, T and Legoux, J.-L and Levache, B and Lobry, C and Lotz, J.-P and Mabro, M and Manet-Lacombe, S and Manfredi, S and Matysiak Budnik, T and Miglianico, L and Mineur, L and Moullet, I and Naman, H and Nouyrigat, P and Oziel-Taieb, S and Perrier, H and Pezet, D and Philip, J and Pottier, V and Porneuf, M and Ramdani, M and Re, D and Rinaldi, Y and Spaeth, D and Taieb, J and Terrebonne, E and Texereau, P and Thirot Bidault, A and Tournigand, C and Tubiana-Mathieu, N and Vantelon, J.-M and Viret, F and Ychou, M and Bangerter, M and Bertram, M.E and ...
Annals of Oncology, ISSN 0923-7534, 09/2013, Volume 24, Issue 9, pp. 2342 - 2349
Journal Article
International Journal of Cancer, ISSN 0020-7136, 10/2004, Volume 111, Issue 6, pp. 921 - 928
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2013, Volume 24, Issue 9, pp. 2335 - 2341
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2016, Volume 27, Issue 1, pp. 140 - 147
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 1/2012, Volume 138, Issue 1, pp. 65 - 72
Panitumumab monotherapy is approved for KRAS wild-type (WT) metastatic colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated... 
Fully human monoclonal antibody | Chemotherapy | Medicine & Public Health | Hematology | Panitumumab | Cancer Research | Internal Medicine | Oncology | Metastatic colorectal cancer | LEUCOVORIN | INITIAL TREATMENT | OXALIPLATIN | FLUOROURACIL | FOLFIRI | PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | CETUXIMAB | ONCOLOGY | IRINOTECAN | KRAS | Camptothecin - adverse effects | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Disease-Free Survival | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Female | Aged | Genes, ras | Camptothecin - analogs & derivatives | Complications and side effects | Cancer patients | Care and treatment | Oncology, Experimental | Colorectal cancer | Monoclonal antibodies | Leucovorin | Metastasis | Research | Fluorouracil | Cancer | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Metastatic colorectal | cancer | Klinisk medicin | Cancer and Oncology | Cancer och onkologi
Journal Article
BMC cancer, ISSN 1471-2407, 2012, Volume 12, Issue 1, pp. 438 - 438
Background: Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal... 
IRINOTECAN FOLFIRI | MANAGEMENT | EFFICACY | Panitumumab | Colorectal cancer | Tolerability | FLUOROURACIL | TUMORS | CHEMOTHERAPY | Quality of life | TRIAL | EGFR INHIBITORS | CETUXIMAB | ONCOLOGY | KRAS | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Skin Diseases - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Skin Diseases - pathology | Young Adult | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Skin - pathology | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Skin Diseases - chemically induced | Mutation - drug effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Aged | Colorectal Neoplasms - pathology | Genes, ras | Skin - drug effects | Usage | Patient outcomes | Analysis | Dosage and administration | Research | Drug therapy | Antimitotic agents | Cancer patients | Care and treatment | Chemotherapy | Epidermal growth factor | Monoclonal antibodies | Skin | Metastasis | Antineoplastic agents | Patient compliance | Cancer | Biotechnology industry | Index Medicus
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 4/2009, Volume 199, Issue 7, pp. 1032 - 1042
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 1569-8041, 2016, Volume 27, Issue 1, p. 140
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2016, Volume 34, Issue 15, pp. e15620 - e15620
Conference Proceeding
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2007, Volume 104, Issue 31, pp. 12907 - 12912
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 8/2010, Volume 122, Issue 3, pp. 883 - 887
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2014, Volume 25, Issue suppl_4, pp. iv175 - iv175
Abstract Aim: The value of low-toxic maintenance treatment (mt) strategies after initial induction chemotherapy in metastatic colorectal cancer (mCRC) remains... 
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2015, Volume 33, Issue 15, pp. 4071 - 4071
Conference Proceeding
BRITISH JOURNAL OF CANCER, ISSN 0007-0920, 11/2016, Volume 115, Issue 10, pp. 1215 - 1222
Background: To investigate tumour biomarker status and efficacy of first-line panitumumab + FOLFIRI for metastatic colorectal carcinoma (mCRC). Methods: 154... 
RAS | PHASE-II | BRAF | OPEN-LABEL | CETUXIMAB TREATMENT | panitumumab | amphiregulin | NRAS | 2ND-LINE THERAPY | SKIN TOXICITY | ONCOLOGY | BRAF MUTATION | response | RAS MUTATIONS | TOXICITY EVALUATION PROTOCOL | GENE-EXPRESSION | metastatic colorectal cancer | KRAS | QUALITY-OF-LIFE
Journal Article
Archives of Pathology and Laboratory Medicine, ISSN 0003-9985, 2002, Volume 126, Issue 6, pp. 702 - 705
Journal Article